Bruce Cree, MD, PhD, MAS, Associate Professor of Clinical Neurology in the Department of Neurology at the University of California San Francisco, discusses two-year data from the open-label extension of the N-MOmentum trial (NCT02200770) of inebilizumab, an FDA-approved treatment for neuromyelitis optica spectrum disorder (NMOSD). These results were presented at the 2021 AAN Annual Meeting.

NMOSD is a rare central nervous disorder that primarily affects the spinal cord and optic nerves. Symptoms of NMOSD  may include blindness in one or both eyes, weakness or paralysis of arms or legs, spasming, loss of sensation, uncontrollable vomiting and hiccups, and bladder/bowel problems due to spinal cord damage.

As Dr. Cree explains, inebilizumab is one of three FDA approved treatments for NMOSD. The approval was based on positive results of the randomized controlled period. The open label extension study that was presented at AAN, included 216 of the 230 participants from the original study. In both the original study and the open-label extension, 87.7% of patients receiving inebilizumab remained attack-free; however, those in the open-label extension remained attack-free for up to 4 years.  Urinary tract infection was the most common adverse treatment effect (placebo: 14.9%; inebilizumab: 7.2%), followed by nasopharyngitis (placebo: 7.1%; inebilizumab: 6.9%) and upper respiratory tract infection (placebo: 4.7%; inebilizumab: 5.7%). Pneumonia also occurred in some patients (placebo: 0.8%; inebilizumab: 0.7%). Overall, the drug continued to provide benefits in the open label extension period similar to those seen in the randomized controlled period. 

To learn more about NMOSD and other neurological disorders, visit